Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss ...

The global motion stimulation therapy market is set for significant growth, with market projections estimating its value at USD 1.4 billion in 2024. Fueled by rapid technological integration in ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...